Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy

固体脂质纳米粒 维尔达格利普汀 医学 药理学 糖尿病性视网膜病变 糖尿病 耐受性 药品 2型糖尿病 不利影响 内分泌学
作者
H. E. Ramadan,Mahmoud M. A. Elsayed,Amani Elsayed,Marwa Fouad,Mohamed S. Mohamed,Sangmin Lee,Reda A. Mahmoud,Shereen A. Sabry,Mohammed M. Ghoneim,Ahmed H.E. Hassan,Reham A. Abd Elkarim,Amany Belal,Ahmed A. El-Shenawy
出处
期刊:International Journal Of Pharmaceutics: X [Elsevier BV]
卷期号:7: 100232-100232 被引量:2
标识
DOI:10.1016/j.ijpx.2024.100232
摘要

Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
AireenBeryl531举报豆芽菜的求助涉嫌违规
刚刚
科目三的应助被木子采纳,获得10
刚刚
正直指甲油完成签到,获得积分20
1秒前
bkagyin的应助被欢喜灵13采纳,获得10
1秒前
顺利一德完成签到,获得积分10
2秒前
ldxghh发布了新的文献求助10
2秒前
来来完成签到,获得积分10
3秒前
3秒前
3秒前
JXY189发布了新的文献求助10
4秒前
4秒前
烟花的应助被科研通管家采纳,获得10
5秒前
江江的应助被科研通管家采纳,获得10
5秒前
Zhou完成签到,获得积分20
5秒前
华仔的应助被科研通管家采纳,获得10
5秒前
5秒前
无极微光的应助被科研通管家采纳,获得20
5秒前
JamesPei的应助被科研通管家采纳,获得10
5秒前
cyy完成签到,获得积分10
5秒前
Owen的应助被科研通管家采纳,获得10
5秒前
5秒前
6秒前
zhonglv7的应助被科研通管家采纳,获得10
6秒前
无极微光的应助被科研通管家采纳,获得20
6秒前
6秒前
爆米花的应助被科研通管家采纳,获得10
6秒前
6秒前
淡淡完成签到,获得积分10
6秒前
斯文败类的应助被科研通管家采纳,获得10
6秒前
6秒前
小虫完成签到,获得积分10
6秒前
kdqiu的应助被yyx采纳,获得10
7秒前
三岁半完成签到,获得积分10
7秒前
8秒前
zzzzz完成签到 ,获得积分10
8秒前
田様的应助被大大魏硕士采纳,获得10
8秒前
momo完成签到,获得积分10
9秒前
9秒前
Maestro_S的应助被Zhou采纳,获得10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181949
求助须知:如何正确求助?哪些是违规求助? 9571702
关于积分的说明 21819272
捐赠科研通 7778399
什么是DOI,文献DOI怎么找? 3433572
关于科研通互助平台的介绍 2557769
邀请新用户注册赠送积分活动 2479630